Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus

Diabetology and Metabolic Syndrome

Volumn 4, Issue 1, 2012, Pages

  Cobble, Michael ^a  

^a Canyons Medical Center   (United States)

Author keywords

efficacy; exenatide; linagliptin; liraglutide; safety; saxagliptin; sitagliptin; type 2 diabetes

Indexed keywords

C PEPTIDE; EXENDIN 4; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCRETIN; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN;

ACUTE PANCREATITIS; ANGIONEUROTIC EDEMA; BODY WEIGHT; BRONCHUS HYPERREACTIVITY; CELL FUNCTION; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE EDEMA; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEALTH CARE COST; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; LONG TERM CARE; MONOTHERAPY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SKIN EXFOLIATION; STEVENS JOHNSON SYNDROME; SYSTOLIC BLOOD PRESSURE; URTICARIA; WEIGHT REDUCTION;

EID: 84857670631     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-4-822390369     Document Type: Review

References (80)

1. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Skyler JS Bergenstal R Bonow RO Buse J, Deedwania P Gale EA, Howard BV Kirkman MS, Kosiborod M Reaven P, Sherwin RS,, Circulation 2009 119 351 357 10.1161/CIRCULATIONAHA.108.191305 19095622
2. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Nathan DM Buse JB Davidson MB Ferrannini E, Holman RR Sherwin R, Zinman B,, Diabetes Care 2009 32 193 203 10.2337/dc08-9025 18945920
3. Statement by an American Association of Clinical Endocrinologists/ American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Rodbard HW Jellinger PS, Davidson JA Einhorn D, Garber AJ Grunberger G, Handelsman Y Horton ES, Lebovitz H Levy P, Moghissi ES Schwartz SS, Endocr Pract 2009 15 540 559 19858063
4. Biology of incretins: GLP-1 and GIP. Baggio LL Drucker DJ, Gastroenterology 2007 132 2131 2157 10.1053/j.gastro.2007.03.054 17498508 (Pubitemid 46711096)
5. Unraveling the science of incretin biology. Nauck MA, Am J Med 2009 122 3 S10 19962494
6. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Naslund E Bogefors J Skogar S Gryback P, Jacobsson H Holst JJ, Hellstrom PM,, Am J Physiol 1999 277 910 R916 10484511
7. Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. Fehmann HC Habener JF, Endocrinology 1992 130 159 166 10.1210/en.130.1.159 1309325
8. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. DeFronzo RA Okerson T, Viswanathan P Guan X, Holcombe JH MacConell L, Curr Med Res Opin 2008 24 2943 2952 10.1185/03007990802418851 18786299
9. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. DeFronzo RA Hissa MN, Garber AJ Gross JL, Duan RY Ravichandran S, Chen RS for the Saxagliptin 014 Study Group, Diabetes Care 2009 32 1649 1655 10.2337/dc08-1984 19478198
10. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Charbonnel B Karasik A Liu J Wu M, Meininger G,, Diabetes Care 2006 29 2638 2643 10.2337/dc06-0706 17130197 (Pubitemid 44912191)
11. Glucagon-like peptide-1 7-36: a physiological incretin in man. Kreymann B Williams G, Ghatei MA Bloom SR, Lancet 1987 2 1300 1304 2890903 (Pubitemid 17156636)
12. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. Nauck MA Heimesaat MM, Behle K Holst JJ, Nauck MS Ritzel R, Hufner M Schmiegel WH, J Clin Endocrinol Metab 2002 87 1239 1246 10.1210/jc.87.3.1239 11889194 (Pubitemid 36121094)
13. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Buse JB Rosenstock J Sesti G Schmidt WE, Montanya E Brett JH, Zychma M Blonde L, for the LEAD-6 Study Group,, Lancet 2009 374 39 47 10.1016/S0140-6736(09)60659- 0 19515413
14. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Chacra AR Tan GH, Apanovitch A Ravichandran S, List J Chen R, Int J Clin Pract 2009 63 1395 1406 10.1111/j.1742-1241.2009.02143.x 19614786
15. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Delgado-Aros S Kim DY, Burton DD Thomforde GM, Stephens D Brinkmann BH, Vella A Camilleri M, Am J Physiol Gastrointest Liver Physiol 2002 282 424 G431 11841992
16. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gutzwiller JP Goke B Drewe J Hildebrand P, Ketterer S Handschin D, Winterhalder R Conen D, Beglinger C,, Gut 1999 44 81 86 10.1136/gut.44.1.81 9862830 (Pubitemid 29143284)
17. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Gutzwiller JP Drewe J Goke B Schmidt H, Rohrer B Lareida J, Beglinger C,, Am J Physiol 1999 276 1541 R1544 10233049
18. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Holst JJ Deacon CF, Diabetologia 2005 48 612 615 10.1007/s00125-005-1705-7 15759106 (Pubitemid 40591213)
19. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. Herman GA Bergman A Stevens C Kotey P, Yi B Zhao P, Dietrich B Golor G, Schrodter A Keymeulen B, Lasseter KC Kipnes MS, Snyder K Hilliard D, Tanen M Cilissen C, De Smet M de Lepeleire I, Van Dyck K Wang AQ, Zeng W Davies MJ, Tanaka W Holst JJ, Deacon CF Gottesdiener KM, Wagner JA,, J Clin Endocrinol Metab 2006 91 4612 4619 10.1210/jc.2006-1009 16912128 (Pubitemid 44833446)
20. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Zhou J Wang X, Pineyro MA Egan JM, Diabetes 1999 48 2358 2366 10.2337/diabetes.48.12.2358 10580424 (Pubitemid 30395427)
21. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Xu G Stoffers DA, Habener JF Bonner-Weir S, Diabetes 1999 48 2270 2276 10.2337/diabetes.48.12.2270 10580413 (Pubitemid 30395416)
22. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Aschner P Kipnes MS, Lunceford JK Sanchez M, Mickel C Williams-Herman DE, Diabetes Care 2006 29 2632 2637 10.2337/dc06-0703 17130196 (Pubitemid 44912190)
23. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Raz I Hanefeld M, Xu L Caria C, Williams-Herman D Khatami H, Diabetologia 2006 49 2564 2571 10.1007/s00125-006-0416-z 17001471
24. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Scott R Wu M, Sanchez M Stein P, Int J Clin Pract 2007 61 171 180 17156104
25. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Mari A Degn K, Brock B Rungby J, Ferrannini E Schmitz O, Diabetes Care 2007 30 2032 2033 10.2337/dc07-0310 17468345 (Pubitemid 47219415)
26. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Rosenstock J Sankoh S List JF,, Diabetes Obes Metab 2008 10 376 386 10.1111/j.1463-1326.2008.00876.x 18355324 (Pubitemid 351524285)
27. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Raz I Chen Y Wu M Hussain S, Kaufman KD Amatruda JM, Langdon RB Stein PP, Alba M,, Curr Med Res Opin 2008 24 537 550 10.1185/030079908X260925 18194595 (Pubitemid 351294402)
28. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Bunck MC Diamant M, Corner A Eliasson B, Malloy JL Shaginian RM, Deng W Kendall DM, Taskinen MR Smith U, Yki-Jarvinen H Heine RJ, Diabetes Care 2009 32 762 768 10.2337/dc08-1797 19196887
29. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Russell-Jones D Vaag A, Schmitz O Sethi BK, Lalic N Antic S, Zdravkovic M Ravn GM, Simo R on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met-SU Study Group, Diabetologia 2009 52 2046 2055 10.1007/s00125-009-1472-y 19688338
30. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Pratley RE Nauck M, Bailey T Montanya E, Cuddihy R Filetti S, Thomsen AB Sondergaard RE, Davies M for the 1860-LIRA-DPP-4 Study Group, Lancet 2010 375 1447 1456 10.1016/S0140-6736(10)60307-8 20417856
31. Byetta [package insert]. San Diego, CA, Amylin Pharmaceuticals, Inc. 2011
32. Victoza [package insert]. Princeton, NJ, Novo Nordisk Inc. 2011
33. Januvia [package insert]. Whitehouse Station, NJ, Merck & Co., Inc. 2011
34. Onglyza [package insert]. Princeton, NJ, Bristol-Myers Squibb Company 2011
35. Tradjenta [package insert]. Ridgefield, CT, Boehringer-Ingelheim Pharmaceuticals, Inc. 2011
36. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Moretto TJ Milton DR Ridge TD Macconell LA, Okerson T Wolka AM, Brodows RG,, Clin Ther 2008 30 1448 1460 10.1016/j.clinthera.2008.08.006 18803987
37. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Garber A Henry R, Ratner R Garcia-Hernandez PA, Rodriguez-Pattzi H Olvera-Alvarez I, Hale PM Zdravkovic M, Bode B for the LEAD-3 (Mono) Study Group, Lancet 2009 373 473 481 10.1016/S0140-6736(08)61246-5 18819705
38. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Vilsboll T Zdravkovic M Le Thi T Krarup T, Schmitz O Courreges JP, Verhoeven R Buganova I, Madsbad S,, Diabetes Care 2007 30 1608 1610 10.2337/dc06-2593 17372153 (Pubitemid 46871185)
39. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Zinman B Hoogwerf BJ, Garcia SD Milton DR, Giaconia JM Kim DD, Trautmann ME Brodows RG, Ann Intern Med 2007 146 477 485 17404349 (Pubitemid 351650556)
40. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Kendall DM Riddle MC Rosenstock J Zhuang D, Kim DD Fineman MS, Baron AD,, Diabetes Care 2005 28 1083 1091 10.2337/diacare.28.5.1083 15855571 (Pubitemid 40616617)
41. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Zinman B Gerich J, Buse JB Lewin A, Schwartz S Raskin P, Hale PM Zdravkovic M, Blonde L for the LEAD-4 Study Investigators, Diabetes Care 2009 32 1224 1230 10.2337/dc08-2124 19289857
42. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Rosenstock J Aguilar-Salinas C, Klein E Nepal S, List J Chen R, Curr Med Res Opin 2009 25 2401 2411 10.1185/03007990903178735 19650754
43. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Rosenstock J Brazg R Andryuk PJ Lu K, Stein P,, Clin Ther 2006 28 1556 1568 10.1016/j.clinthera.2006.10.007 17157112 (Pubitemid 44841980)
44. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Hanefeld M Herman GA, Wu M Mickel C, Sanchez M Stein PP, Curr Med Res Opin 2007 23 1329 1339 10.1185/ 030079907X188152 17559733 (Pubitemid 46998442)
45. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Del Prato S Barnett AH, Huisman H Neubacher D, Woerle HJ Dugi KA, Diabetes Obes Metab 2011 13 258 267 10.1111/j.1463-1326.2010. 01350.x 21205122
46. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Pratley R Nauck M Bailey T Montanya E, Cuddihy R Filetti S, Garber A Thomsen AB, Hartvig H Davies M, for the 1860-LIRA-DPP-4 Study Group,, Int J Clin Pract 2011 65 397 407 10.1111/j.1742-1241.2011.02656.x 21355967
47. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Arnolds S Dellweg S Clair J Dain MP, Nauck MA Rave K, Kapitza C,, Diabetes Care 2010 33 1509 1515 10.2337/dc09-2191 20357372
48. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Scheen AJ Charpentier G Ostgren CJ Hellqvist A, Gause-Nilsson I,, Diabetes Metab Res Rev 2010 26 540 549 10.1002/dmrr.1114 20824678
49. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Blonde L Klein EJ, Han J Zhang B, Mac SM Poon TH, Taylor KL Trautmann ME, Kim DD Kendall DM, Diabetes Obes Metab 2006 8 436 447 10.1111/j.1463-1326.2006.00602.x 16776751 (Pubitemid 44349236)
50. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Hermansen K Kipnes M, Luo E Fanurik D, Khatami H Stein P, Diabetes Obes Metab 2007 9 733 745 10.1111/j.1463-1326.2007.00744.x 17593236 (Pubitemid 47261855)
51. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Taskinen MR Rosenstock J Tamminen I Kubiak R, Patel S Dugi KA, Woerle HJ,, Diabetes Obes Metab 2011 13 65 74 10.1111/j.1463-1326.2010.01326.x 21114605
52. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Nelson P Poon T, Guan X Schnabel C, Wintle M Fineman M, Diabetes Technol Ther 2007 9 317 326 10.1089/dia.2006.0024 17705687 (Pubitemid 47340082)
53. AACE/ACE diabetes algorithm for glycemic control (update). American Association of Clinical Endocrinologists/American College of Endocrinology. Rodbard HW Jellinger PS, Davidson JA Einhorn D, Garber AJ Grunberger G, Handelsman Y Horton ES, Lebovitz H Levy P, Moghissi ES Schwartz SS, 2009 https://www.aace.com/sites/default/files/GlycemicControlAlgorithmPPT.pdf Accessed December 7, 2011
54. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Heine RJ Van Gaal LF, Johns D Mihm MJ, Widel MH Brodows RG, Ann Intern Med 2005 143 559 569 16230722
55. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Nauck M Frid A, Hermansen K Shah NS, Tankova T Mitha IH, Zdravkovic M During M, Matthews DR for the LEAD-2 Study Group, Diabetes Care 2009 32 84 90 10.2337/dc08-1355 18931095
56. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Marre M Shaw J, Brandle M Bebakar WM, Kamaruddin NA Strand J, Zdravkovic M Le Thi TD, Colagiuri S on behalf of the LEAD-1 SU Study Group, Diabet Med 2009 26 268 278 10.1111/j.1464-5491.2009.02666.x 19317822
57. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Brazg R Xu L, Dalla MC Cobelli C, Thomas K Stein PP, Diabetes Obes Metab 2007 9 186 193 10.1111/j.1463-1326.2006.00691.x 17300594 (Pubitemid 46206562)
58. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Del Prato S Barnett AH, Huisman H Neubacher D, Woerle HJ Dugi KA, Diabetes Obes Metab 2011 13 258 267 10.1111/j.1463-1326.2010. 01350.x 21205122
59. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Klonoff DC Buse JB, Nielsen LL Guan X, Bowlus CL Holcombe JH, Wintle ME Maggs DG, Curr Med Res Opin 2008 24 275 286 18053320 (Pubitemid 351160260)
60. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. Hollander P Li J, Allen E Chen R, J Clin Endocrinol Metab 2009 94 4810 4819 10.1210/jc.2009-0550 19864452
61. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Zander M Madsbad S, Madsen JL Holst JJ, Lancet 2002 359 824 830 10.1016/S0140-6736(02)07952-7 11897280 (Pubitemid 34233752)
62. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Nauck MA Duran S, Kim D Johns D, Northrup J Festa A, Brodows R Trautmann M, Diabetologia 2007 50 259 267 10.1007/s00125-006-0510-2 17160407
63. Guide for aviation medical examiners. Pharmaceuticals (Therapeutic medications). Diabetes mellitus- type II, medication controlled (not insulin). Federal Aviation Administration, 2011 http://www.faa.gov/about/office-org/ headquarters-offices/avs/offices/aam/ame/guide/pharm/oral-diabetes/. Accessed December 7, 2011
64. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. DeFronzo RA Ratner RE, Han J Kim DD, Fineman MS Baron AD, Diabetes Care 2005 28 1092 1100 10.2337/diacare.28.5.1092 15855572 (Pubitemid 40616618)
65. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Buse JB Henry RR, Han J Kim DD, Fineman MS Baron AD, Diabetes Care 2004 27 2628 2635 10.2337/diacare.27.11. 2628 15504997 (Pubitemid 39441462)
66. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Noel RA Braun DK, Patterson RE Bloomgren GL, Diabetes Care 2009 32 834 838 10.2337/dc08-1755 19208917
67. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Dore DD Seeger JD Arnold CK,, Curr Med Res Opin 2009 25 1019 1027 10.1185/03007990902820519 19278373
68. Weighing risks and benefits of liraglutide - the FDA's review of a new antidiabetic therapy. Parks M Rosebraugh C, N Engl J Med 2010 362 774 777 10.1056/NEJMp1001578 20164475
69. Byetta. NDA approval. Supplemental approval. US Food and Drug Administration 2009 http://www.accessdata.fda.gov/drugsatfda-docs/appletter/ 2009/021773s009s011s017s018s022s025021919ltr.pdf Accessed November 29, 2011
70. Victoza. NDA approval. US Food and Drug Administration 2010 http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/022341s000approv.pdf Accessed November 29, 2011
71. Januvia. Supplement approval. US Food and Drug Administration 2010 http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2010/ 021995s010s011s012s014ltr.pdf Accessed November 29, 2011
72. Onglyza. NDA approval. US Food and Drug Administration 2009 http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2009/022350s000ltr.pdf Accessed November 29, 2011
73. Tradjenta. NDA Approval. US Food and Drug Administration 2011 http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2011/201280s000ltr.pdf Accessed November 29, 2011
74. Exenatide-associated ischemic renal failure. Weise WJ Sivanandy MS, Block CA Comi RJ, Diabetes Care 2009 32 22 e23 19171732
75. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Knudsen LB Madsen LW, Andersen S Almholt K, de Boer AS Drucker DJ, Gotfredsen C Egerod FL, Hegelund AC Jacobsen H, Jacobsen SD Moses AC, Molck AM Nielsen HS, Nowak J Solberg H, Thi TDL Zdravkovic M, Endocrinology 2010 151 1473 1486 10.1210/en.2009-1272 20203154
76. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. Misurski D Lage MJ, Fabunmi R Boye KS, Appl Health Econ Health Policy 2009 7 245 254 19905038
77. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine. Fabunmi R Nielsen LL Quimbo R Schroeder B, Misurski D Wintle M, Wade R,, Curr Med Res Opin 2009 25 777 786 10.1185/03007990802715199 19203299
78. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. Sullivan SD Alfonso-Cristancho R Conner C Hammer M, Blonde L,, Pharmacotherapy 2009 29 1280 1288 10.1592/phco.29.11.1280 19873688
79. Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. Buse JB Garber A, Rosenstock J Schmidt WE, Brett JH Videbaek N, Holst J Nauck N, J Clin Endocrinol Metab 2011 96 1695 1702 10.1210/jc.2010-2822 21450987
80. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. Amori RE Lau J, Pittas AG, JAMA 2007 298 194 206 10.1001/jama.298.2.194 17622601 (Pubitemid 47057766)